MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:MBX - CA59501P1045 - Common Stock
0.24 CAD
-0.01 (-2.04%)
We assign a fundamental rating of 4 out of 10 to MBX. MBX was compared to 23 industry peers in the Biotechnology industry. While MBX seems to be doing ok healthwise, there are quite some concerns on its profitability. MBX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
MBX had negative earnings in the past year.
In the past year MBX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: MBX reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MBX reported negative operating cash flow in multiple years.
1.2 Ratios
MBX has a Return On Assets of -6.00%. This is amongst the best in the industry. MBX outperforms 86.96% of its industry peers.
MBX's Return On Equity of -8.08% is amongst the best of the industry. MBX outperforms 86.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6% | ||
| ROE | -8.08% | ||
| ROIC | N/A |
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MBX's Gross Margin of 53.02% is amongst the best of the industry. MBX outperforms 82.61% of its industry peers.
In the last couple of years the Gross Margin of MBX has grown nicely.
The Profit Margin and Operating Margin are not available for MBX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
2. Health
2.1 Basic Checks
MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MBX has more shares outstanding
MBX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MBX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.77, we must say that MBX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.77, MBX belongs to the top of the industry, outperforming 86.96% of the companies in the same industry.
MBX has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.24, MBX perfoms like the industry average, outperforming 56.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.77 |
ROIC/WACCN/A
WACC7.45%
2.3 Liquidity
A Current Ratio of 8.48 indicates that MBX has no problem at all paying its short term obligations.
MBX has a better Current ratio (8.48) than 91.30% of its industry peers.
MBX has a Quick Ratio of 5.17. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX has a better Quick ratio (5.17) than 86.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.48 | ||
| Quick Ratio | 5.17 |
3. Growth
3.1 Past
The earnings per share for MBX have decreased strongly by -163.28% in the last year.
Looking at the last year, MBX shows a very negative growth in Revenue. The Revenue has decreased by -26.81% in the last year.
MBX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.05% yearly.
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
3.2 Future
The Earnings Per Share is expected to grow by 52.75% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 29.96% on average over the next years. This is a very strong growth
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 5.94, which indicates a rather cheap valuation of MBX.
Based on the Price/Forward Earnings ratio, MBX is valued cheaply inside the industry as 95.65% of the companies are valued more expensively.
MBX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.94 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MBX is valued cheaply inside the industry as 91.30% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 146.32 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX's earnings are expected to grow with 52.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
MBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MBX (1/12/2026, 7:00:00 PM)
0.24
-0.01 (-2.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.76%
Ins Owner ChangeN/A
Market Cap33.36M
Revenue(TTM)18.59M
Net Income(TTM)-2.25M
Analysts80
Price Target0.51 (112.5%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-44.44%
PT rev (3m)-44.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.94 | ||
| P/S | 1.79 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.2 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | 146.32 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.04
Fwd EY16.83%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.13
BVpS0.2
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6% | ||
| ROE | -8.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.02% | ||
| FCFM | N/A |
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
F-Score2
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 34.25 | ||
| Cap/Depr | 44.81% | ||
| Cap/Sales | 4.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.48 | ||
| Quick Ratio | 5.17 | ||
| Altman-Z | 1.77 |
F-Score2
WACC7.45%
ROIC/WACCN/A
Cap/Depr(3y)83.66%
Cap/Depr(5y)119.48%
Cap/Sales(3y)5.99%
Cap/Sales(5y)7.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-139.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-135.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.85%
OCF growth 3YN/A
OCF growth 5YN/A
MICROBIX BIOSYSTEMS INC / MBX.CA FAQ
What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA.
What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.
What is the profitability of MBX stock?
MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 3 / 10.